DÄ internationalArchiveReferences

Review article

Non-Alcoholic Fatty Liver Disease

Dtsch Arztebl Int 2014; 111(26): 447-52. DOI: 10.3238/arztebl.2014.0447

Weiß, J; Rau, M; Geier, A

1.Chalasani N, Younossi Z, Lavine JE, et al.: The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the American Association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association. Hepatology 2012; 55: 2005–23. CrossRef MEDLINE
2.Younossi ZM, Stepanova M, Afendy M, et al.: Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9: 524–30. CrossRef MEDLINE
3.Blachier M, Leleu H, Peck-Radosavljevic M, Valla DC, Roudot-Thoraval F: The burden of liver disease in Europe. A Review of available epidemiological data. European Association for the Study of the Liver 2013. J Hepatol 2013; 58: 593–608. CrossRef MEDLINE
4.Angulo P: Non alcoholic fatty liver disease. N Engl J Med 2002; 346: 1221–31. CrossRef MEDLINE
5.OECD Health Data 2012; Eurostat Statistics Database. WHO Global Infobase. http://dx.doi.org/10.1787/9789264183896-en (last accessed on 15 April 2014). CrossRef
6.Ayonrinde OT, Olynyk JK, Beilin LJ, et al.: Gender-specific differences in adipose distribution and adipocytokines influence adolescent nonalcoholic fatty liver disease. Hepatology 2011; 53: 800–9. CrossRef MEDLINE
7.Koehler EM, Schouten JNL, Hansen BE, et al.: Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: Results from the Rotterdam study. J Hepatol 2012; 57: 1305–11. CrossRef MEDLINE
8.Lee JY, Kim KM, Lee SG, et al.: Prevalence and risk factors of non alcoholic fatty liver disease in potential living liver donors in Korea: a review of 589 consecutive liver biopsies in a single center. J Hepatol 2007; 47: 239–44. CrossRef MEDLINE
9.Vernon G, Baranova A, Younossi ZM: Systematic review: the epidemiology and natural history of non alcoholic fatty liver disease and non alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274–85. CrossRef MEDLINE
10.Ahima RS, Lazar MA: The Health risk of obesity–better metrics imperative. Science 2013; 341: 856–8. CrossRef MEDLINE
11.Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR: Prevalence and associated factors in non alcoholic fatty liver disease in patients with type 2 diabetes mellitus. Liver Int 2009; 29: 113–9. CrossRef MEDLINE
12.Teli MR, James OF, Burt AD, Bennett MK, Day CP: The natural history of non alcoholic fatty liver: a follow up study. Hepatology 1995; 22: 1714–9. CrossRef MEDLINE
13.Caldwell SH, Crespo DM: The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol 2004; 40: 578–84. CrossRef MEDLINE
14.Bataller R, Rombouts K, Altamirano J, Marra F: Fibrosis in alcoholic and non alcoholic steatohepatitis. Best Pract Res Clin Gastroenterol 2011; 25: 231–44. CrossRef MEDLINE
15.Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN: The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010; 51: 1972–8. CrossRef MEDLINE
16.Ertle J, Dechêne A, Sowa JP, et al.: Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer 2011; 128: 2436–43. CrossRef MEDLINE
17.El-Serag HB, Davila JA, Petersen NJ, McGlynn KA: The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 2003; 139: 817–23. CrossRef MEDLINE
18.Stepanova M, Younossi ZM: Independent association between nonalcoholic fatty liver disease and cardiovascular disease in the US population. Clin Gastroenterol Hepatol 2012; 10: 646–50. CrossRef MEDLINE
19.Ekstedt M, Franzén LE, Mathiesen UL, et al.: Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006; 44; 865–73. CrossRef MEDLINE
20.Adams LA, Lymp JF, St Sauver J, et al.: The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113–21. CrossRef MEDLINE
21.Moretto M, Kupski C, da Silva VD, Padoin AV, Mottin CC: Effect of bariatric surgery on liver fibrosis. Obes Surg 2012; 22: 1044–9. CrossRef MEDLINE
22.Zelber-Sagi F, Lotan R, Shlomai A, et al.: Predictors for incidence and remission of NAFLD in the general population during a seven-year prospective follow-up. J Hepatol 2012; 56; 1145–51. CrossRef MEDLINE
23.Anty R, Marjoux S, Ianelli A, et al.: Regular coffee but not espresso drinking is protective against fibrosis in a cohort mainly composed of morbidly obese European women with NAFLD undergoing bariatric surgery. J Hepatol 2012; 57: 1090–6. CrossRef MEDLINE
24.Dunn W, Sanyal AJ, Brunt EM, et al.: Modest alcohol consumption is associated with decreased steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J Hepatol 2012; 57: 384–91. CrossRef MEDLINE PubMed Central
25.Fracanzani AL, Valenti L, Bugianesi E, et al.: Risk of severe liver disease in nonalcoholic fatty liver disease in normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology 2008; 48: 792–8. CrossRef MEDLINE
26.Merriman RB, Ferrell LD, Patti MG, et al.: Correlation of paired liver biopsies in morbidly obese patients with suspected nonalcoholic fatty liver disease. Hepatology 2006; 44: 874–80. CrossRef MEDLINE
27.Malek NP, Schmidt S, Huber P, Manns MP, Greten TF: Diagnose und Therapieoptionen beim hepatozellulären Karzinom. Dtsch Arztebl Int 2014; 111: 101–6. VOLLTEXT
28.Machado MV, Cortez-Pinto H: Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal. J Hepatol 2013; 58: 1007–19. CrossRef MEDLINE
29.Gaia S, Carenzi S, Barilli AL, et al.: Reliability of transient elastography for the detection of fibrosis in non-alcoholic fatty liver disease and chronic viral hepatitis. J Hepatol 2011; 54: 64–71. CrossRef MEDLINE
30.Angulo P, Bugianesi E, Bjornsson ES, et al.: Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 782–9. CrossRef MEDLINE
31.Angulo P, Keach JC, Batts KP, Lindor KD: Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999; 30: 1356–62. CrossRef MEDLINE
32.Romeo S, Kozlitina J, Xing C, et al.: Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet 2008; 40: 1461–5. CrossRef MEDLINE PubMed Central
33.Trépo E, Nahon P, Bontempi G, et al.: Association between the PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma: evidence from a meta-analysis of individual participant data. Hepatology 2013; doi: 10.1002/hep.26767 (Epub ahead of print). CrossRef MEDLINE
34.Pomrath K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR: Randomized controlled trial testing the effects of weight loss on nonalcolholic steatohepatitis. Hepatology 2010; 51: 121–9. CrossRef MEDLINE PubMed Central
35.Chen HP, Shieh JJ, Chang CC, et al.: Metformin decreases hepatocellular carcinoma risk in dose-dependend manner: population-based and in vitro studies. Gut 2013; 62: 606–15. CrossRef MEDLINE
36.Zhang H, Gao C, Fang L, Zhao HC, Yao SK: Metformin and reduced risk of hepatocellular carcinoma in diabetic patients: a meta-analysis. Scand J Gastroenterol 2013; 48: 78–87. CrossRef MEDLINE
37.Belfort R, Harrison SA, Brown K, et al.: A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 2006; 355; 2297–307. CrossRef MEDLINE
38.Sanyal AJ, Chalasani L, Kowdley KV, et al.: Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675–85. CrossRef MEDLINE PubMed Central
39.Targher G, Bertolini L, Scala L, et al.: Associations between serum 25-hydroxy vitamin D3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr Metab Cardiovasc Dis 2007; 17; 517–24. CrossRef MEDLINE
40.Geier A: Shedding new light on vitamin D and fatty liver disease. J Hepatol 2011; 55: 273–5. CrossRef MEDLINE
e1.Soresi M, Giannitrapani L, Florena AM, et al.: Reliability of the bright liver echo pattern in diagnosing steatosis in patients with cryptogenic and HCV-related hypertransaminasaemia. Clin Radiol 2009; 64: 1181–7. CrossRef MEDLINE
e2.Marcos A, Fisher RA, Ham JM, et al.: Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation 2000; 69: 2410–15. CrossRef MEDLINE
e3.Williams CD, Stenger J, Asike MI, et al.: Prevalence of non alcoholic fatty liver disease and non alcoholic steatohepatitis among a largely middle aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011: 140: 124–31. CrossRef MEDLINE
e4.Flegal KM, Kit BK, Orpana H, Graubard BI: Association of all-cause mortality with overweight and obesity using standard body mass categories: a systematic review and meta-analysis. JAMA 2013; 309: 71–82. CrossRef MEDLINE
e5.Assy N, Kaita K, Mymin D, Levy C, Rosser B, Minuk G: Fatty infiltration of liver in hyperlipidemic patients. Dig Dis Sci 2000; 45: 1929–34. CrossRef MEDLINE
e6.Clark JM, Brancati FL, Diehl AM: The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol 2003; 98: 960–7. CrossRef MEDLINE
e7.Browning JD, Kumar KS, Saboorian MH, Thiele DL: Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol 2004; 99: 292–8. CrossRef MEDLINE
e8.Robert Koch-Institut, Gesellschaft der epidemiologischen Krebsregsiter in Deutschland e.V. (eds.): Krebs in Deutschland 2009/2010. 9th edition. Berlin: Robert Koch-Institut 2013; 40.
e9.Altekruse SF, McGlynn KA, Reichman ME: Hepatocellular carcinoma incidence, mortality and survival trends in the United States from 1975 to 2005. J Clin Oncol 2009; 27: 1485–91. CrossRef MEDLINE PubMed Central
e10.Mottin CC, Moretto M, Padoin AV, et al.: Histological behavior of hepatic steatosis in morbidly obese patients after weight loss induced by bariatric surgery. Obes Surg 2005; 15: 788–93. CrossRef MEDLINE
e11.Kahraman A, Sowa JP, Schlattjan M et al.: Fetuin mRNA expression is elevated in NASH compared with NAFL patients. Clin Sci (Lond) 2013; 125: 391–400. CrossRef MEDLINE
e12.Canbay A, Feldstein A, Kronenberger B, Schulze-Osthoff K, Bantel H: Zytokeratin-18 als Marker zur nicht invasiven Diagnostik und Prognose akuter und chronischer Lebererkrankungen. Z Gastroenterol 2014; 52: 290–5. CrossRef MEDLINE
e13.Tannapfel H, Dienes HP, Lohse AW: The indications for liver biopsy. Dtsch Arztebl Int 2012; 109: 477–83. VOLLTEXT
e14.Wiegand J, Berg T: The etiology, diagnosis and prevention of liver cirrhosis—part 1 of a series of liver cirrhosis. Dtsch Arztebl Int 2013; 110: 85–91. VOLLTEXT
e15.Valenti L, Al-Serri A, Daly AK, et al.: Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 1209–17. CrossRef MEDLINE
e16.Lewis JR, Mohanty SR: Nonalcoholic fatty liver disease: a review and update. Dig Dis Sci 2010; 55: 560–78. CrossRef MEDLINE
e17.Yamauchi T, Kamon J, Minokoshi Y, et al.: Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 2002; 8: 1288–95. CrossRef MEDLINE
e18.Cusi K: Role of obesity and lipotoxicity in the development of non-alcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology 2012; 142: 711–25. CrossRef MEDLINE


Figures and tables